top of page

Debiopharm reaches key development milestones for Staphylococcus-selective antibiotic Debio 1450

Debiopharm International has announced various significant achievements in the development of its new antibiotic Debio 1450, selectively active on staphylococcal species including hard-to-treat methicillin-resistant Staphylococcus aureus (MRSA).



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page